Prescription Drugs · Immunology & Inflammation Therapeutics
AbbVie revenue, results and funding
AbbVie filed revenue of $61.2B for 2025.
Data updated Nov 19, 2026 · Back to the company report
$61.2BRevenue, 2025
$4.2BNet income, 2025
ABBVNew York Stock Exchange
Results by year
| Year | Revenue | Net income | Total assets | LANG_CR_S_M_TAX_PAID | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_DIVIDENDS | LANG_CR_S_M_BUYBACKS | LANG_CR_S_M_CAPEX | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_OPERATING_INCOME | LANG_CR_S_M_CASH | LANG_CR_S_M_DEBT | LANG_CR_S_M_ACQUISITIONS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $61.2B | $4.2B | $134B | $3.6B | $2.4B | $11.7B | $980M | $1.2B | $955M | $9.1B | $15.1B | $5.2B | $64.5B | $204M |
| 2024 | $56.3B | $4.3B | $135.2B | $4.1B | −$570M | $11B | $1.7B | $974M | $911M | $12.8B | $9.1B | $5.5B | $66.8B | $17.5B |
| 2023 | $54.3B | $4.9B | $134.7B | $4.7B | $1.4B | $10.5B | $2B | $777M | $747M | $7.7B | $12.8B | $12.8B | $59.2B | $0 |
| 2022 | $58.1B | $11.8B | $138.8B | $3B | $1.6B | $10B | $1.5B | $695M | $671M | $6.5B | $18.1B | $9.2B | $63.1B | $255M |
| 2021 | $56.2B | $11.5B | $146.5B | $3.6B | $1.4B | $9.3B | $934M | $787M | $692M | $6.9B | $17.9B | $9.7B | $76B | $525M |
| 2020 | $45.8B | $4.6B | $150.6B | $1.7B | −$1.2B | $7.7B | $978M | $798M | $753M | $6.4B | $11.4B | $8.4B | $84.9B | $38.3B |
| 2019 | $33.3B | $7.9B | $89.1B | $1.4B | $544M | $6.4B | $629M | $552M | $430M | $6.4B | $13B | $39.9B | $67.2B | $0 |
| 2018 | $32.8B | $5.7B | $59.4B | – | −$490M | $5.6B | $12B | $638M | $421M | $10.3B | $6.4B | $7.3B | – | $0 |
| 2017 | $28.2B | $5.3B | $70.8B | $1.7B | $2.4B | $4.1B | $1.4B | $529M | $365M | $5B | $9.5B | $9.3B | – | $0 |
| 2016 | $25.6B | $6B | $66.1B | $3.6B | $1.9B | $3.7B | $6B | $479M | $353M | $4.4B | $9.3B | $5.1B | – | $2.5B |
| 2015 | $22.9B | $5.1B | $53.1B | $1.1B | $1.5B | $3.3B | $7.6B | $532M | $282M | $4.3B | $7.5B | $8.4B | – | $11.5B |
| 2014 | $20B | $1.8B | $27.5B | $498M | $595M | $2.7B | $665M | $612M | $241M | $3.3B | $3.4B | $8.3B | – | $622M |
| 2013 | $18.8B | – | $29.2B | $1.3B | $1.2B | $2.6B | $320M | $491M | $212M | $2.9B | $5.7B | $9.6B | – | $405M |
| 2012 | $18.4B | – | $27B | – | $450M | – | – | $333M | $187M | $2.8B | $5.8B | $5.9B | – | $688M |
| 2011 | $17.4B | – | – | – | $235M | – | – | $356M | $163M | $2.6B | $3.6B | $27M | – | $273M |
Sources: SEC
How to cite
AbbVie, Financials. Alion, Nov 19, 2026. https://alion.io/company/abbvie/financials
